Dr. Vijay Mallya resigns as the Chairman of the Board of Bayer CropScience Limited w.e.f. June 30, 2016
Bayer CropScience Limited regretfully accepts the voluntary resignation of Dr. Vijay Mallya as its Director and Chairman. Dr. Mallya was appointed Chairman of the Board in March 2004. During his tenure, Bayer CropScience has grown significantly into a market leading position. Bayer CropScience is extremely grateful for Dr. Mallya’s professionalism, dedication and loyalty. Bayer CropScience and its promoter, Bayer AG, thank Dr. Mallya for his valuable service and wish him all the best for his future. Bayer CropScience Limited will appoint a new Chairman at the next Board Meeting.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.in
Corporate Communications, Bayer Group in India
Tel.: +9122-25311234; E-mail: firstname.lastname@example.org
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.